Eyenuk
eyenuk.com
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
Eyenuk develops EyeArt, an autonomous artificial intelligence system that screens retinal photographs for diabetic retinopathy and other eye disease. Founded in 2010 in California, its software is cleared in the United States and Europe and used in primary care clinics. The company also researches retinal biomarkers for cardiovascular and neurological conditions.
News
Eyenuk Appoints Mads Dall as Chairman of the Board and Gaurav Agarwal as Chief Executive Officer
media506807,506808,506809
Read more
Report
Eyenuk's New FDA Clearance Could Boost Adoption for Its Diabetic Retinopathy Screening Tech
Eyenuk recently received FDA clearance to use the Topcon NW400 retinal camera with its EyeArt AI system, which automatically detects diabetic retinopathy. The company said this FDA clearance makes its system the only AI system that is FDA-cleared for use
Read more
Report
Eyenuk raises $26M for diabetic retinopathy screening tech
Eyenuk, a company that makes technology for eye screenings, raised $26 million in a Series A funding round, bringing its total funding to more than $43 million. Research shows that the company's AI system is more accurate in detecting diabetic retinopathy
Read more
Report
Eyenuk secures $26 Million Series A funding to accelerate global access to AI-powered eye-screening technology
/CNW/ -- Eyenuk, Inc. ("Eyenuk" or "Company"), a global artificial intelligence (AI) digital health company and the leader in real-world applications for AI...
Read more
Report
Pro access
Upgrade to see all 11 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.